Exscientia

Sanofi | May 09, 2017

Under the alliance, Exscientia will use its platform to seek out and validate combinations of drug targets that could work synergistically and be amenable to its bispecific-small-molecule design strategy....

Pharmaphorum Media Limited | March 22, 2019

AI drug R&D firm Ex Scientia has announced it has expanded into Japan, after clinching a major research deal with Celgene. Based in Oxford, UK, Ex Scientia said it has established a subsidiary, Ex Scientia K.K. which is to spearhead its pharmaceutical interests across Asia. Exscientia K.K. is headquartered in Osaka, Japan, and led by Dr. Daisuke Tanaka, an experienced medicinal chemist who previously was director of the Innovative Chemistry Group at Sumitomo Dainippon Pharma (DSP).Dr. ...

GSK | April 05, 2019

AI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D tie-up signed in 2017. Under the deal Exscientia will develop small molecule drugs for up to 10 disease targets nominated by GSK, and is worth up to £33 million if all these milestones are met. The Oxford biotech gave no details about how much it got paid for submitting this first active lead molecule for development by GSK, but said it is a highly potent in vivo ...

pharmaphorum | June 12, 2019

UK Artificial Intelligence (AI) drug discovery firm Exscientia has begun a collaboration with Chinas GT Apeiron Therapeutics, focusing on oncology. As part of the agreement, Exscientia gets share options in GT Apeiron as well as receiving milestones and royalties based on the clinical, regulatory and commercial success of each programme. GT Apeiron was launched by GT Healthcare Capital Partners, a life science-focused private equity partnership, with $27 million financial backing. Exscientia wil...